非小细胞肺癌脑转移的靶向和免疫治疗 |
| |
引用本文: | 宋琪,焦顺昌,李方. 非小细胞肺癌脑转移的靶向和免疫治疗[J]. 中国肺癌杂志, 2016, 0(8): 530-532. DOI: 10.3779/j.issn.1009-3419.2016.08.08 |
| |
作者姓名: | 宋琪 焦顺昌 李方 |
| |
作者单位: | 解放军总医院肿瘤内一科, 北京,100853 |
| |
摘 要: | 脑转移是非小细胞肺癌(non-small cell lung cancer, NSCLC)常见并发症,发生率为30%-50%,大大影响了患者的生存质量。NSCLC一旦发生脑转移预后极差,未经治疗者的中位生存期仅为1个月-2个月。基于肺癌驱动基因的靶向治疗为肺癌脑转移提供了新的方法。目前免疫治疗已成为肿瘤治疗的新方向,它能通过刺激机体免疫系统提高抗肿瘤免疫效应。临床上靶向治疗和免疫治疗的结合运用可使患者获益。
|
关 键 词: | 肺肿瘤 脑转移 靶向治疗 免疫治疗 |
Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer with Brain Metastasis |
| |
Abstract: | Brain metastasis, a common complication of non-small cell lung cancer (NSCLC) with an incidence rate of 30%-50%, signiifcantly affects the patients’ quality of life. hTe prognosis of patients of NSCLC with brain metastasis is ex-tremely poor, the average median survival is only 1 m-2 m without treatment. hTe targeted therapy based on lung cancer driven gene is a new treatment. Besides, the immunotherapy which can enhance the effect of anti-cancer by simulating the immune system is a new approach. The combination of targeted therapy and immunotherapy can greatly benefit patients in clinical work. |
| |
Keywords: | Lung neoplasms Brain metastasis Immunotherapy Targeted therapy |
本文献已被 万方数据 等数据库收录! |
|